Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Paclitaxel and Cisplatin With or Without Endocrine Therapy in Locally Advanced Breast Cancer
NCT02221999Phase 3Active, not recruiting
- Sponsor
- Renji Hospital
- Start
- Sep 2013
- Primary completion
- Jan 2019
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of letrozole and gonadotropin-releasing hormone agonist in breast cancer (3 arms), sponsored by Renji Hospital. Primary endpoint: Pathological Complete Remission Rate at 4 months. Started Sep 2013; status: active, not recruiting.
02
Drugs
letrozolegonadotropin-releasing hormone agonist
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02221999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221999.